ÂÜÀòÂÒÂ×

Carly joined the AMR Action Fund as an analyst in November 2021. She received her MS in cell biology and PhD in microbiology at Rutgers University. During her doctoral and post-doctoral research, she developed and evaluated a novel anti-tubercular drug candidate. Additionally, she used a multi-omics approach to characterize the physiology of drug-tolerant Mycobacterium tuberculosis isolates. Carly's scientific work has led to several publications and recognition through various awards.